6.41

1.76% -0.11

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $6.41, with a volume of 673.60K. It is down -1.76% in the last 24 hours and up +0.71% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$6.52

Open:

$6.6

24h Volume:

673.60K

Relative Volume:

0.78

Market Cap:

$301.40M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-2.4098

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

+14.38%

1M Performance:

+0.71%

6M Performance:

-56.46%

1Y Performance:

-77.32%

1-Day Range:

$6.39

$6.77

1-Week Range:

$5.29

$6.91

52-Week Range:

$4.4301

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

201

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	6.405	301.40M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	473.57	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.57	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.51	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.50	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.28	28.75B	3.30B	-501.07M	1.03B	-2.1146

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

10:32 AM

There Is A Lot Of Upside Potential For 4D Molecular Therapeutics Inc(NASDAQ: FDMT) - Stocks Register

10:32 AM

Feb 06, 2025

A better buy-in window may exist right now for 4D Molecular Therapeutics Inc (FDMT) - SETE News

Feb 06, 2025

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends - News & Insights

Feb 06, 2025

Feb 05, 2025

Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex

Feb 05, 2025